{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-26-005989","form_type":"8-K","ticker":"PBSV","cik":"0001304161","company_name":"Pharma-Bio Serv, Inc.","filed_at":"2026-06-15T21:06:05+00:00","discovered_at":"2026-06-15T21:08:00.384328+00:00","generated_at":"2026-06-15T21:08:08.193685+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Pharma-Bio Serv Q1 revenue $2.7M, net income $0.2M; both up YoY","bullets":["Three-month revenue $2.7M, up $0.3M vs prior year; net income $0.2M, up $0.1M.","Six-month revenue $5.0M, up $0.1M; net income $0.3M, up $0.2M.","CEO cites strategic focus on high-return markets and cost management for profit improvement."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-26-005989","json":"https://secwatch.observer/filing/0001654954-26-005989.json","markdown":"https://secwatch.observer/filing/0001654954-26-005989.md","text":"https://secwatch.observer/filing/0001654954-26-005989.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1304161/000165495426005989/0001654954-26-005989-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1304161/000165495426005989/pbsv_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T21:08:08.193685+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"25a278e3178d9c3bd8fcfa9f15ec919e4d4155b5","claim":"Pharma-Bio Serv, Inc. reported the quarter ended April 30, 2026 results: revenue approximately $2.7 million, net income approximately $0.2 million.","evidence_excerpt":"revenues for the three and six months ended April 30, 2026 were approximately $2.7 million and $5.0 million, respectively, representing increases of approximately $0.3 million and $0.1 million compared to the same periods last year. Net income for the three and six months ended April 30, 2026 was approximately $0.2 million and $0.3 million, respectively, representing increases of approximately $0.1 million and $0.2 million compared to the same periods last year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1304161/000165495426005989/0001654954-26-005989-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended April 30, 2026"},{"label":"Revenue","value":"approximately $2.7 million"},{"label":"Net income","value":"approximately $0.2 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"4d8af7c326b3cbcf1abec1fa2ba00e34e9eefa83","claim":"Pharma-Bio Serv, Inc. reported the six months ended April 30, 2026 results: revenue approximately $5.0 million, net income approximately $0.3 million.","evidence_excerpt":"revenues for the three and six months ended April 30, 2026 were approximately $2.7 million and $5.0 million, respectively, representing increases of approximately $0.3 million and $0.1 million compared to the same periods last year. Net income for the three and six months ended April 30, 2026 was approximately $0.2 million and $0.3 million, respectively, representing increases of approximately $0.1 million and $0.2 million compared to the same periods last year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1304161/000165495426005989/0001654954-26-005989-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the six months ended April 30, 2026"},{"label":"Revenue","value":"approximately $5.0 million"},{"label":"Net income","value":"approximately $0.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}